Clinical Competition Candidate
REVLIMID
REVLIMID carries substance and product and use-code patents, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 20 months away. Active clinical competition may compress the generic entry window.
LOE window
20months
to latest listed patent expiry (March 8, 2028)
Expiry attractiveness: 5/5
Patent profile
Substance patent (listed)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 2
Complexity score: 1/5
Clinical competition
Score: 5/5
Active trials linked: 300
Phase 2/3 trials: 219
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: LENALIDOMIDE
Applicant (NDA holder): BRISTOL MYERS SQUIBB
Confidence: High